Antimicrobial or wound care materials, devices and uses

12064,523

18/215019

June 27, 2023

An antimicrobial material including a composite of a matrix component comprising a flexible hydrophilic polymer foam or fiber matrix comprising two matrix faces providing a release face and a reverse face or two release faces, and therebetween a structural matrix framework defining a network of cells having a cell network surface and therein a network of pores or cell openings, and a powder charge component comprising antimicrobial additive or wound care additive, wherein said powder charge is comprised at one said release face or both said faces and/or within said cell network.

Smith & Nephew PLC (Watford, GB)

Smith & Nephew PLC (Watford, GB)

1. Material which is a wound care material comprising: a flexible polymer foam or fibre matrix comprising a wound facing face and a reverse face or two wound facing faces and therebetween a structural matrix defining a cell network, and a powder charge comprising a wound dressing additive, wherein said powder charge is comprised at said wound facing face or said reverse face and within said cell network, wherein said powder charge is within said cell network in diminishing amount with increasing depth within said cell network, and wherein more than 50% of the powder charge is present within 0.8 mm from a surface of the flexible polymer foam or fibre matrix.

2. The material of claim 1 , wherein the powder charge further comprises a flowing agent selected from a group consisting of clay, silica, charcoal, graphite and a combination thereof and the flowing agent has a particle size distribution D50<10 micron.

3. The material of claim 1 , wherein wound dressing additive or combinations thereof, is selected from any of antimicrobial species-releasing additive and wound dressing additive selected from antimicrobial, bacterial, bacteriostatic, fireproofing, odour control, activated charcoal or bentonite, protein-breaking or denaturisation, wicking, conductive, structure-supporting, absorbent, superabsorbent polymer (SAP), colour or colour masking, optical brighteners, oxidation prevention.

4. The material of claim 1 , wherein more than 70% of the powder charge is present within 0.8 mm from the surface of the wound facing face.

5. The material of claim 1 , wherein the powder charge extends up to 50% of a separation between the wound facing face and the reverse face.

6. The material of claim 1 , wherein the powder charge is localized in nodes.

7. A method of treating a wound, comprising: placing a wound dressing comprising a loaded wound dressing layer into or over the wound, wherein the loaded wound dressing layer comprises a porous matrix and a powder charge of antimicrobial release additive loaded within the porous matrix, wherein more than 50% of the powder charge is present within 0.8 mm from a surface of a wound facing surface, and wherein the antimicrobial release additive is activated for release of an antimicrobial agent into the wound from the wound dressing upon contact with moist or aqueous medium.

8. A wound dressing, comprising: a loaded wound dressing layer comprising: a porous matrix comprising a wound facing face and a reverse face; and a powder charge of antimicrobial release additive loaded within the porous matrix, wherein the powder charge decreases in amount with increasing distance from the wound facing face and more than 50% of the powder charge is present within 0.8 mm from a surface of the wound facing face.

9. The wound dressing of claim 8 , wherein the powder charge further comprises a flowing agent selected from a group consisting of clay, silica, charcoal, graphite and a combination thereof.

10. The wound dressing of claim 9 , wherein the flowing agent has a particle size distribution D50<10 micron.

11. The wound dressing of claim 8 , wherein the porous matrix comprises a hydrophilic polymer foam.

12. The wound dressing of claim 8 , wherein the antimicrobial release additive comprises elemental silver, silver salts, silver complexes, caged forms thereof, caged forms of iodine and combinations thereof.

13. The wound dressing of claim 8 , wherein the antimicrobial release additive is selected from a group consisting of silver sulfadiazine, silver zeolite, silver sulfate, silver carbonate, silver chloride, silver nitrate, silver oxide, silver phosphate, silver citrate, silver acetate, silver lactate, cadexomer iodine and combinations thereof.

14. The wound dressing of claim 8 , wherein the antimicrobial release additive is in an amount of 1.4 mg/cm 2 to 4 mg/cm 2 at the wound facing face.

15. The wound dressing of claim 8 , further comprising a wound contact layer below the loaded wound dressing layer.

16. The wound dressing of claim 8 , further comprising a cover layer over the loaded wound dressing layer and further comprising a fluidic connector configured to connect the cover layer to a source of negative pressure.

17. The wound dressing of claim 8 , further comprising an absorbent layer over the loaded wound dressing layer and the absorbent layer comprises superabsorbent particles.

18. The wound dressing of claim 8 , wherein the powder charge further comprises a superabsorbent polymer.

19. The wound dressing of claim 9 , wherein a particle size of the flowing agent is less than the antimicrobial release additive.

20. The wound dressing of claim 8 , wherein the porous matrix comprises a plurality of cells and wherein the antimicrobial release additive is at least partially embedded within said plurality of cells.

4340043 July 1982 Seymour
4559050 December 1985 Iskra
4728323 March 1988 Matson
5147338 September 1992 Lang et al.
6488670 December 2002 Schild et al.
8084663 December 2011 Watson, Jr.
8263100 September 2012 Areskoug et al.
9345803 May 2016 Bradford
9877872 January 2018 Mumby et al.
11730854 August 2023 Dagger
20040091677 May 2004 Topolkaraev
20060127437 June 2006 Kennedy et al.
20070122462 May 2007 Chandra et al.
20070275043 November 2007 Freeman et al.
20100055437 March 2010 Fink et al.
20100260824 October 2010 Shah et al.
20110144599 June 2011 Croizat et al.
20120130332 May 2012 Cotton et al.
20120177720 July 2012 Patel et al.
20120322903 December 2012 Karandikar et al.
20140107555 April 2014 Patel
20140249495 September 2014 Mumby et al.
20140276491 September 2014 Luckemeyer et al.
20140336557 November 2014 Durdag et al.
20150283287 October 2015 Agarwal et al.
20160045635 February 2016 Jayakody et al.
20160228909 August 2016 Marduel
20170098818 April 2017 Cheng et al.
20180125721 May 2018 Hoggarth et al.
20190083675 March 2019 Carr et al.
20200188550 June 2020 Dagger et al.
20210146000 May 2021 Dagger et al.
20220118151 April 2022 Gardiner et al.
2523365 October 2004
101862470 October 2010
203576752 May 2014
0059049 September 1982
0065370 November 1982
1964580 September 2008
2653140 March 2015
2833929 July 2016
2145126 March 1985
2537840 November 2016
WO-9636757 November 1996
WO-9636758 November 1996
WO-03055941 July 2003
WO-03097727 November 2003
WO-2011077096 June 2011
WO-2014074503 May 2014
WO-2014086186 June 2014
WO-2014140608 September 2014
WO-2018115453 June 2018
WO-2019012068 January 2019
WO-2019012069 January 2019
WO-2019012072 January 2019

BBC Bitesite, “Rates of Reaction,” National 5 Chemistry Revision, Retrieved from the Internet: www.bbc.co.uk/bitesize/guides/zct4fcw/revision/4 , accessed on Mar. 4, 2022, 36 pages. cited by applicant
Hu J., “Practical Hospital Pharmacy 2nd Edition,” 2007, 7 pages. cited by applicant
International Preliminary Report on Patentability for Application No. PCT/EP2018/069015, mailed on Jan. 23, 2020, 10 pages. cited by applicant
International Search Report and Written Opinion, for Application No. PCT/EP2018/069015, mailed on Nov. 9, 2018, 12 pages. cited by applicant
Mao L., “Medicinal Aerosols,” 1996, 8 pages. cited by applicant
“Pharmacopoeia of the People's Republic of China,” compiled by the Pharmacopoeia Committee of the Ministry of Health of the People's Republic of China, 1995, p. 1120. cited by applicant
Search Report under Section 17(5) mailed Jan. 11, 2018 for Great Britain Application No. 1711183.2, 5 pages. cited by applicant
Search Report under Section 17(6) mailed Jul. 23, 2018 for Great Britain Application No. 1711183.2, 3 pages. cited by applicant
Woo K.Y., et al., “A Randomized Controlled Trial to Evaluate an Antimicrobial Dressing with Silver Alginate Powder for the Management of Chronic Wounds,” Advances in Skin and Wound Care, vol. 25, No. 11, Nov. 2012, pp. 503-508. cited by applicant
Zhao Y., “Key Technology about Traditional Chinese Medicine and Natural Product Extraction and Preparation,” Chapter 16, Section 1, 2012, 7 pages. cited by applicant

edspgr.12064523